City page
Stockholm biotech and pharma directory
Stockholm anchors Swedish biotech around Karolinska Institutet and SciLifeLab — the country's flagship medical research and infrastructure platform. The commercial layer includes Sobi (rare disease, hemophilia therapeutics), BioArctic (CNS, Alzheimer's antibody Lecanemab co-developer with Eisai), Hansa Biopharma (transplant immunology), Orexo, plus a long tail of mid-cap biotech operators and translational spinouts. Solna hosts the Karolinska Solna campus and many associated companies.
Where does this city read strongest?
Therapeutics (7), CDMO (1), and Manufacturing (1). Most visible records: IDL Diagnostics, AnaCardio, and Atlas Antibodies.
Which standards and public evidence are already visible?
GMP (2). Latest review: 22 March 2026. Review cycle: March 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Stockholm.
By category
Stockholm by category
Jump into a category page filtered to this country only.
Full list
Stockholm biotech and pharma directory
11 city records currently match the active filter.
Current review cycle
IDL Diagnostics
StockholmSwedenDiagnostics
Bromma diagnostics company, formerly AroCell, operating as IDL Diagnostics with a Swedish IVD portfolio spanning oncology and bacteriology testing.
- Lead
- Anders HultmanCEO
- Scale
- Diagnostics platform
Current review cycle
AnaCardio
StockholmSwedenTherapeutics
Stockholm clinical-stage biopharmaceutical company developing novel contractile agents for heart failure from a Swedish operating base.
- Lead
- Patrik StrombergCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Atlas Antibodies
StockholmSwedenTools
Stockholm life-science tools company developing, manufacturing, and distributing validated antibodies and reagents derived from the Human Protein Atlas ecosystem.
- Lead
- Dan PituliaGroup Chief Executive Officer
- Scale
- Research-tools platform
Current review cycle
Diamyd Medical
StockholmSwedenTherapeutics
Stockholm biotech company developing precision immunotherapies for type 1 diabetes, with Swedish clinical-development operations and a linked production footprint in Umea.
- Lead
- Ulf HanneliusPresident and CEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Calliditas Therapeutics
StockholmSwedenTherapeutics
Stockholm specialty-pharma company developing and commercializing therapies for orphan renal and hepatic diseases from its Swedish headquarters.
- Lead
- Renee Aguiar-LucanderCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Modus Therapeutics
StockholmSwedenTherapeutics
Stockholm biotech company developing sevuparin-based therapeutics for sepsis, severe systemic inflammation, malaria, and related anemia states from a Swedish public-company base.
- Lead
- John OhdChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Oncopeptides
StockholmSwedenTherapeutics
Stockholm oncology company focused on targeted peptide-drug conjugate therapies and related cancer-treatment programs.
- Lead
- Jakob LindbergCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
BioArctic
StockholmSwedenTherapeutics
Stockholm therapeutics company focused on neurodegenerative diseases, including Alzheimer's and Parkinson's, through antibody and disease-modifying drug programs.
- Lead
- Gunilla OsswaldCEO
- Scale
- Clinical-stage biotech platform
Current review cycle
Recipharm
StockholmSwedenCDMO
Stockholm-headquartered CDMO network spanning sterile, oral, and advanced pharmaceutical manufacturing across Europe.
- Lead
- Greg BeharChief Executive Officer
- Scale
- International CDMO manufacturing
Current review cycle
Sobi
StockholmSwedenTherapeutics
Stockholm rare-disease headquarters and technical-operations node used as a Nordic benchmark surface for executive review.
- Lead
- Guido OelkersChief Executive Officer
- Scale
- Global rare-disease operations
Current review cycle
Valneva Sweden
StockholmSwedenManufacturing
Swedish Valneva operating site covering Stockholm and Solna coordinates within the company?s vaccine manufacturing and development network.
- Lead
- Thomas LingelbachChief Executive Officer, Member of the Board of Directors
- Scale
- Commercial scale
FAQ
Frequently asked questions
- Why is Stockholm important for biotech?
- Stockholm hosts Karolinska Institutet (one of Europe's top medical universities), SciLifeLab (Sweden's flagship life-sciences infrastructure), and a substantial commercial biotech cohort. The Solna campus connects industry to research; major biotech companies cluster around the Karolinska ecosystem.
- What biotech companies are headquartered in Stockholm?
- Sobi (Swedish Orphan Biovitrum — rare disease, hemophilia, immunology), BioArctic (Alzheimer's antibody Lecanemab co-developer with Eisai), Hansa Biopharma (transplant immunology — IgG-degrading enzymes), Orexo, plus mid-cap and emerging biotech anchored by the Karolinska Institutet ecosystem.
- What sectors are strongest in Stockholm biotech?
- Stockholm is strongest in CNS / neuroscience (BioArctic's Alzheimer's antibody program), rare-disease therapeutics (Sobi), transplant immunology (Hansa), translational research (Karolinska + SciLifeLab pipeline), and biotech tools/diagnostics anchored by the Solna ecosystem.
Related briefs
Briefs that mention Stockholm
European mRNA & Immunotherapy Supply Chain 2026
Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.
Open briefNordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefEuropean Antibody & Biosimilar Therapeutics 2026: mAbs, ADCs, Biosimilars
A practical map of the European antibody + antibody-drug-conjugate + biosimilar therapeutics sector in 2026 — Genmab, ADC Therapeutics, Adcendo, Affimed, Tubulis, Heidelberg Pharma, Sandoz, Mabion, plus a Swedish + Swiss + Polish antibody innovator belt.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.